The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

A groundbreaking study by the National Institutes of Health (NIH) is shifting the conversation around hormone therapy and ...